Compare PATK & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATK | IMNM |
|---|---|---|
| Founded | 1959 | 2006 |
| Country | United States | United States |
| Employees | N/A | 177 |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 1994 | 2020 |
| Metric | PATK | IMNM |
|---|---|---|
| Price | $84.50 | $22.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $122.75 | $32.80 |
| AVG Volume (30 Days) | 918.1K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $29,000,000.00 | $6,941,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $6.51 | $1,127.34 |
| P/E Ratio | $77.68 | ★ N/A |
| Revenue Growth | ★ 262.50 | N/A |
| 52 Week Low | $81.29 | $8.67 |
| 52 Week High | $148.50 | $27.65 |
| Indicator | PATK | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 51.66 |
| Support Level | $82.49 | $19.28 |
| Resistance Level | $90.28 | $23.25 |
| Average True Range (ATR) | 2.70 | 1.15 |
| MACD | 0.17 | -0.15 |
| Stochastic Oscillator | 39.18 | 17.01 |
Patrick Industries Inc is a component solutions provider for the recreational vehicle (RV), marine, powersports, manufactured housing (MH), and various industrial markets, including single and multi-family housing, hospitality, institutional, and commercial markets. The company operates within two reportable segments, Manufacturing and Distribution. The majority of its revenue is generated from the Manufacturing segment, which offers laminated products utilized to produce furniture, shelving, walls, and countertops; fabricated aluminum products; cabinet products, doors, components, and custom cabinetry; interior passage doors and baggage doors; RV and marine furniture, etc. Geographically, the company mainly operates in the United States, with a small presence in Mexico, China, and Canada.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.